Luma Health vs Bristol Myers Squibb

Side-by-side comparison of AI visibility scores, market position, and capabilities

Bristol Myers Squibb leads in AI visibility (80 vs 38)
Luma Health logo

Luma Health

EmergingHealthcare

Patient Engagement

Patient engagement platform with automated SMS reminders, self-scheduling, and EHR integration for health systems; $130M+ a16z-backed competing with Phreesia for healthcare communication automation.

AI VisibilityBeta
Overall Score
D38
Category Rank
#453 of 596
AI Consensus
84%
Trend
stable
Per Platform
ChatGPT
34
Perplexity
38
Gemini
34

About

Luma Health is a San Francisco-based patient engagement and care orchestration platform that automates patient communication and administrative workflows for healthcare providers — providing appointment reminders, two-way SMS messaging, self-scheduling, waitlist management, referral coordination, and broadcast messaging that integrate directly with major electronic health record (EHR) systems including Epic, Cerner, Athenahealth, and eClinicalWorks. Backed by Andreessen Horowitz and other investors with $130+ million raised, Luma Health serves health systems, hospital groups, and ambulatory practices seeking to reduce no-shows and improve patient access.

Full profile
Bristol Myers Squibb logo

Bristol Myers Squibb

LeaderHealthcare Tech

Enterprise

Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.

AI VisibilityBeta
Overall Score
A80
Category Rank
#18 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
78
Perplexity
78
Gemini
80

About

Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).

Full profile

AI Visibility Head-to-Head

38
Overall Score
80
#453
Category Rank
#18
84
AI Consensus
83
stable
Trend
stable
34
ChatGPT
78
38
Perplexity
78
34
Gemini
80
38
Claude
84
40
Grok
77

Key Details

Category
Patient Engagement
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Luma Health
Patient Engagement

Integrations

Only Bristol Myers Squibb
Bristol Myers Squibb is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.